Remove 2020 Remove Clinical Trials Remove DEA
article thumbnail

NORML Formally Responds to DEA’s Proposed Changes to Marijuana Cultivation Rules

NORML

Under existing regulations, the agency only licenses one facility — the University of Mississippi — to cultivate cannabis for use in FDA-approved clinical trials. To date, however, the DEA has failed to either affirm or reject any of the more than 30 applications it has received.

article thumbnail

NORML “Senate Unanimously Approves Legislation Providing US Attorney General with Greater Say in Cannabis Research Decisions”

Cannabis Law Report

Senate Bill 253: The Cannabidiol and Marihuana Research Expansion Act provides the office of US Attorney General, rather than the US Drug Enforcement Administration, the discretion to license scientists to engage in clinical trials involving the use of cannabis by human subjects. Senate members in 2020 passed a similar version of S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Psychedelic Revolution Version 2.0: Save Lives & Dismantle War on Fungus

NewsMunchies

In clinical trials, psilocybin (the psychoactive substance in mushrooms) has shown tremendous promise in treating severe depression, post-traumatic stress disorder, and other mental illnesses. Additional clinical trials underway in the U.S. While the science on psychedelics is exploding, there are roadblocks in the way.

article thumbnail

U.S. Funding Focuses on Marijuana’s Harms, Not Benefits

CannaMD

In March 2020, after nearly four years of delays, the U.S. Drug Enforcement Agency (DEA) announced that it will evaluate 37 additional grower applications. One such rule requires that all growers turn over all marijuana and by-products to the DEA shortly after harvest. The DEA would then be the exclusive distributor.

DEA 105
article thumbnail

New Frontiers in the Law of Psychedelics

Cannabis Law Report

On November 3, 2020, Oregon became the first state to decriminalize psilocybin for recreational purposes. Then, in November 2019, the FDA granted the designation to the nonprofit Usona Institute to study psilocybin’s effect on major depressive order, for which clinical trials are currently under way. 360bbb-0a(a)(2).

Law 81
article thumbnail

Bank of America Shuts Down Cannabis Research Facility Account

Cannabis Law Report

Bank of America (BoA) is reportedly terminating its banking relationship with Scottsdale Research Institute (SRI), a DEA-registered facility that carries out important marijuana research. The quality of this cannabis had been criticised by a number of researchers, including Dr. Sisley.

Banking 52
article thumbnail

Veterans Try Cannabis To Treat PTSD

SpeedWeed

CANNABIS CULTURE – The results are now in after the first-ever legal clinical trial into the use of cannabis to treat PTSD, but did the DEA’s rules taint the outcome? Seventy-six mostly male veterans between the ages of 24 and 77 completed the Phase 1 trial.